Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue SUPPL. 3, 2009, Pages

  Searles, Gordon ^{a,b,c,d,e,f,g}   Bissonnette, Robert ^{a,b,c,d,e,f,g}   Landells, Ian ^{a,b,c,d,e,f,g}   Shear, Neil H ^{a,b,c,d,e,f,g}   Papp, Kim ^{a,b,c,d,e,f,g}   Lui, Harvey ^{a,b,c,d,e,f,g}  

^a Keystone Dermatology Institute   (Canada)

^b INNOVADERM RESEARCH   (Canada)

^c Nexus Clinical Research Inc   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e PROBITY MEDICAL RESEARCH   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CYCLOSPORIN; METHOTREXATE; RETINOID; TOPICAL AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANADA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE REGISTRY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHASE 4 CLINICAL TRIAL; PHOTOTHERAPY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS VULGARIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CANADA; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MORBIDITY; PROSPECTIVE STUDIES; PSORIASIS; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74349106048     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2009.00031     Document Type: Article

References (28)

1. Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther 2008;21:54-9.
2. Debertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:729-36.
3. Gupta AK, Langley R, Poulin Y, et al. Pathogenesis of psoriasis and current challenges. J Cutan Med Surg 2004;8 Suppl:3-7.
4. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
5. National Psoriasis Foundation. National Psoriasis Foundation 2008 survey panel snapshot. Available at: http://psoriasis.org/files/pdfs/research/ 2008_fall_survey_panel.pdf (accessed November 8, 2008).
6. Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg 2004;8:321-37.
7. Sterry W, Barker J, Boehncke W-H, et al. Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004;151 Suppl 69:3-17.
8. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004;50:416-30.
9. Smith EC, Riddle C, Menter MA, Lebwohl M. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008;47:514-8.
10. Lebwohl M, Colon LE. The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis. Cutis 2007;80(5 Suppl):29-40.
11. Zachariae C, Mørk NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008;88:495-501.
12. Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2007;158:1345-9.
13. Koo JY, Bagel J, Sweetser MT, Ticho BS. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol 2006;5:623-8.
14. Kircik L, Bagel J, Korman N, et al; the UNITE Study Group. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008;7:245-53.
15. Gade JN. Clinical update on alefacept: consideration for use in patients with psoriasis. J Manag Care Pharm 2004;10(3 Suppl B):S33-7.
16. Lebwohl M, Christophers E, Langley R, et al, for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27.
17. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33.
18. Legat FJ, Hofer A, Wackernagel A, et al. Narrowband UV-B phototherapy, alefacept and clearance of psoriasis. Arch Dermatol 2008;144:1067-8.
19. Ortonne JP, Khemis A, Koo JY, Choi J. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005;19:556-63.
20. Mease PJ, Gladman DD, Keystone EC; Alefacept in Psoriatic Arthritis Study Group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:1638-45.
21. Van Duijnhoven MW, de Jong EM, Gerritsen WJ, et al. Alefacept modifies long-term disease severity and improves the response to other treatments. Eur J Dermatol 2005;15:366-73.
22. Perlmutter A, Cather J, Franks B, et al. Alefacept revisited: our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008;58:116-24.
23. Krueger GG, Gottlieb AB, Sterry W, et al. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatolog Treat 2008;19:146-55.
24. Langewouters AM, Van Erp PE, De Jong EM, Van De Kerkhof PC. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) antipsoriatics in refractory psoriasis. J Dermatolog Treat 2006;17:362-9.
25. Bissonnette R, Searles G, Landells I, et al. The AWARE study: methodology and baseline characteristics. J Cutan Med Surg 2009;13 Suppl 3:113-21.
26. Wexler D, Searles G, Landells I, et al. Update on alefacept safety. J Cutan Med Surg 2009;13 Suppl 3:139-47.
27. Landells I, Searles G, Bissonnette R, et al. Efficacy outcomes in patients using alefacept in the AWARE study. J Cutan Med Surg 2009;13 Suppl 3:122-30.
28. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007;57:957-62.